Heatwurx (NASDAQ:PCSA) Issues Quarterly Earnings Results

Heatwurx (NASDAQ:PCSA) released its quarterly earnings data on Friday. The company reported ($61.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($60.58), FiscalAI reports.

Heatwurx Price Performance

Shares of NASDAQ:PCSA traded up $0.02 during trading hours on Friday, hitting $1.86. The company’s stock had a trading volume of 18,724 shares, compared to its average volume of 121,503. Heatwurx has a 52 week low of $1.04 and a 52 week high of $8.88. The company has a market capitalization of $5.21 million, a price-to-earnings ratio of -0.44 and a beta of 1.24. The firm’s fifty day moving average price is $1.81 and its 200 day moving average price is $2.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Heatwurx in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Heatwurx

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.